Atossa Therapeutics could benefit from Trump-era tariffs and received analyst attention regarding its strategic moves.
1 report, 0 independent
Updated Jul 3
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Atossa Therapeutics could benefit from Trump-era tariffs and received analyst attention regarding its strategic moves.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Atossa Therapeutics (United States)
company in Seattle, United States
Nothing else this week.
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
Related events
- Barclays raised its price target for Okta, noting that AI stocks are benefiting from the onshoring trend and Trump-era tariffs.
- Trump's tariff plan caused markets to tank, impacting Donnelley Financial Solutions.
- Trump's tariff plan caused markets to tank, affecting company Flo.
- Goldman Sachs and Zeta Interactive noted that tariffs and onshoring benefit AI stocks, citing accelerated Q2 growth and raising price targets.
- Aggressive tariff plan caused market tanking, impacting Cincinnati Financial.
Coverage
Newest first; wire copies grouped- Unknown outlet